AACR 2013: NCI-Sponsored Session: The Cancer Genome Atlas (TCGA) A Rapidly Expanding Community Resource: Status; Review of Data Dissemination

Monday, April 08, 2013, 2:30 PM - 3:30 PM
Room 140, Washington Convention Center, D.C.

The Cancer Genome Atlas (TCGA) has a goal of describing the genomic changes in more than 25 types of human cancer over the next several years. With the support of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), a robust collaborative network of institutions and investigators has been established to accrue and process specimens and generate comprehensive, multi-dimensional genomic data, creating an invaluable community resource. Moreover, this comprehensive program continues to generate data across many other tumor types selected for analyses as well as include more data types, such as protein arrays, pathology reports and diagnostic images. 

The session will report TCGA progress toward the 25 tumor project goal, the expansion to include over a dozen rare malignancies, as part of TCGA’s Rare Tumor Project, and beginning analysis across tumor types. To date, TCGA has completed the integrative genomic characterizations of glioblastoma, ovarian serous adenocarcinoma, colorectal carcinoma, lung squamous cell carcinoma, and breast ductal carcinoma and also, has accrued more than 500 tumors for papillary thyroid, clear cell kidney, and endometrial cancer. Although TCGA has analyzed thousands of cases across 25 subtypes, a major challenge has been the dissemination of TCGA data in ways to maximize their utility to multiple types of users. Speakers will discuss the plans and progress toward integrating and visualizing these complex data and innovative approaches for the generation of “bioinformatic and analysis pipelines.” In addition, data from specific tumor projects will be used to provide examples of how high-quality, multi-dimensional data sets from robust numbers of high-quality samples can be interrogated by the cancer research community to generate novel insights.

Chairperson: Kenna Shaw, National Cancer Institute, Bethesda, MD

  • TCGA: Strategy, Goals and Overall Status: Kenna Shaw, National Cancer Institute, Bethesda, Md.
  • Using the TCGA Data Portal: Data Types and Function: Liming Yang, National Cancer Institute, Bethesda, Md.
  • Applying for Access to Controlled Databases: Brad Ozenberger, National Human Genome Research Institute, Bethesda, Md.
  • Examples of Integrated Analysis and Tools for Interacting and Understanding TCGA Data: Nikolaus Schultz, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
  • Summary and Q&A: Kenna Shaw, National Cancer Inst., Bethesda, Md. and Brad Ozenberger. National Human Genome Research Institute, Bethesda, Md.